IDEAYA is a synthetic lethality-focused precision medicine oncology company. We are passionately pursuing the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA has a world-class team of leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development. Our Scientific Advisory Board (SAB) consists of academic and industry thought leaders including members of the National Academy of Sciences and the National Academy of Medicine.
O ur team has built a robust pipeline of potential first-in-class and/or best-in-class precision medicine therapeutics. We have an ongoing target identification, validation and drug discovery research focus in synthetic lethality – an emerging class of precision medicine targets. Our most advanced pipeline programs include IDE397, a clinical stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion, which represents approximately 15% of solid tumors, as well as IDE196, a clinical stage PKC inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Since inception, IDEAYA’s research focus has been to exploit the concept of synthetic lethality, an approach for indirectly targeting oncogenic pathways. Certain genetic alterations in cancer cells enable tumor proliferation, but also create vulnerabilities – which we target with our therapeutics. In cancer cells with such genetic alterations, pharmacological inhibition of the target can cause cell death. In normal cells, without such genetic alternations, the target inhibition can be non-lethal – creating a therapeutic window. Patients for our therapeutics are selected using molecular diagnostics to identify the genetic alternation or a related biomarker.
We have established a strategic partnership with GlaxoSmithKline (GSK) on our Pol Theta and Werner Helicase synthetic lethality programs, and are collaborating with Pfizer pursuant to a clinical trial collaboration and supply agreement on our PKC program.
IDEAYA is headquartered in South San Francisco, California.
Scientific Advisory Board
William R. Sellers, M.D.
Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
Board of Directors
Garret Hampton, Ph.D.
Director | President, Clinical Sequencing and Oncology, ThermoFisher Scientific
Catherine Mackey, Ph.D.
Director | Former Senior Vice President of Pfizer Worldwide Research and Development